$JBIO News

Jade Biosciences: Duration Is The Real Product

Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $47

Jade Biosciences Q2 EPS $(0.76) Misses $(0.64) Estimate

Jade Biosciences Enters Exclusive Worldwide License Agreement With Paragon Therapeutics; To Pay Up To $22M In Milestone Payments To Paragon; To Pay Paragon Low To Mid-Single-Digit Percentage Royalties On Net Sales Of Licensed Products; Paragon Barred From New Campaigns Targeting Licensed Target For At Least Five Years

Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

UBS Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $45

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Reported Earlier, Jade Biosciences Prices $150M Stock Offering Of 10M Shares at $15 Each

Jade Biosciences Announces Pricing of Public Offering of Common Stock

Jade Biosciences Announces Proposed Underwritten Public Offering

Jade Biosciences Reveals Proposed Underwritten Public Offering; No Size Disclosed

Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $45

Jade Biosciences: Strong Early Signal, But Still A Wait For Proof

Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials

Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript

Why Is Jade Biosciences Stock Trading Lower On Monday?

BTIG Maintains Buy on Jade Biosciences, Raises Price Target to $74

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

HC Wainwright & Co. Maintains Buy on Jade Biosciences, Raises Price Target to $55